Published in Genes Dev on May 15, 2008
Mutant p53: one name, many proteins. Genes Dev (2012) 4.33
The p53 orchestra: Mdm2 and Mdmx set the tone. Trends Cell Biol (2010) 3.08
The Mdm2-p53 relationship evolves: Mdm2 swings both ways as an oncogene and a tumor suppressor. Genes Dev (2010) 2.27
Dietary downregulation of mutant p53 levels via glucose restriction: mechanisms and implications for tumor therapy. Cell Cycle (2012) 1.32
The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med (2011) 1.28
The receptor interacting protein 1 inhibits p53 induction through NF-kappaB activation and confers a worse prognosis in glioblastoma. Cancer Res (2009) 1.22
Bioinformatics analysis of metastasis-related proteins in hepatocellular carcinoma. World J Gastroenterol (2008) 0.87
Epigenetic linkage of aging, cancer and nutrition. J Exp Biol (2015) 0.83
Surfing the p53 network. Nature (2000) 35.36
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature (2005) 18.30
Live or let die: the cell's response to p53. Nat Rev Cancer (2002) 15.06
Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature (2005) 14.65
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
The p53-mdm-2 autoregulatory feedback loop. Genes Dev (1993) 11.19
Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature (1995) 10.18
Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature (1995) 8.68
Signaling to p53: breaking the MDM2-p53 circuit. Cell (1998) 8.63
Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 8.48
mdm2 expression is induced by wild type p53 activity. EMBO J (1993) 8.01
The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev (1998) 7.46
Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 7.22
The p53 pathway. J Pathol (1999) 6.79
The differential effects of mutant p53 alleles on advanced murine lung cancer. Cancer Res (2005) 5.93
Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med (2004) 5.48
Post-translational modifications and activation of p53 by genotoxic stresses. Eur J Biochem (2001) 5.43
Tumor surveillance via the ARF-p53 pathway. Genes Dev (1998) 5.11
The ubiquitin ligase COP1 is a critical negative regulator of p53. Nature (2004) 5.05
Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell (2003) 4.96
ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor. Cell (2005) 4.60
TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene (2007) 4.27
Gain of function mutations in p53. Nat Genet (1993) 4.19
A dynamic role of HAUSP in the p53-Mdm2 pathway. Mol Cell (2004) 4.05
MDM2 inhibitors for cancer therapy. Trends Mol Med (2006) 3.88
p53 gain-of-function cancer mutants induce genetic instability by inactivating ATM. Nat Cell Biol (2007) 3.86
Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci U S A (1996) 3.38
The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev (2008) 3.17
Structure-function-rescue: the diverse nature of common p53 cancer mutants. Oncogene (2007) 2.96
MDM2, an introduction. Mol Cancer Res (2003) 2.87
Targeted inactivation of Mdm2 RING finger E3 ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer Cell (2007) 2.42
Mdm2 is critically and continuously required to suppress lethal p53 activity in vivo. Cancer Cell (2006) 2.32
p53 protein stability in tumour cells is not determined by mutation but is dependent on Mdm2 binding. Oncogene (1997) 2.31
MDM2 promotes proteasome-dependent ubiquitin-independent degradation of retinoblastoma protein. Mol Cell (2005) 2.29
MDM2 promotes p21waf1/cip1 proteasomal turnover independently of ubiquitylation. EMBO J (2003) 2.13
The chaperone-associated ubiquitin ligase CHIP is able to target p53 for proteasomal degradation. J Biol Chem (2005) 2.01
Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function? Oncogene (2007) 1.97
MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem (2004) 1.93
Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development. Proc Natl Acad Sci U S A (2006) 1.82
Transcription regulation by mutant p53. Oncogene (2007) 1.78
Ubiquitination and degradation of mutant p53. Mol Cell Biol (2007) 1.77
Unleashing the power of p53: lessons from mice and men. Genes Dev (2006) 1.76
Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53. J Biol Chem (2004) 1.66
A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network. Cancer Cell (2006) 1.64
The conformationally flexible S9-S10 linker region in the core domain of p53 contains a novel MDM2 binding site whose mutation increases ubiquitination of p53 in vivo. J Biol Chem (2002) 1.50
Enhanced Mdm2 activity inhibits pRB function via ubiquitin-dependent degradation. EMBO J (2004) 1.47
Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J (2006) 1.45
Chaperone-dependent stabilization and degradation of p53 mutants. Oncogene (2008) 1.37
Improving cancer therapy by non-genotoxic activation of p53. Eur J Cancer (2003) 1.37
Distinct roles of Mdm2 and Mdm4 in red cell production. Blood (2006) 1.36
Binding of p53 to the central domain of Mdm2 is regulated by phosphorylation. J Biol Chem (2006) 1.26
Loss of Mdm4 results in p53-dependent dilated cardiomyopathy. Circulation (2007) 1.21
Human tumor p53 mutations are selected for in mouse embryonic fibroblasts harboring a humanized p53 gene. Proc Natl Acad Sci U S A (2004) 1.16
Small-molecule inhibitors of the p53 suppressor HDM2: have protein-protein interactions come of age as drug targets? Trends Pharmacol Sci (2004) 1.13
A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway. Oncogene (2004) 1.12
Mouse mutants reveal that putative protein interaction sites in the p53 proline-rich domain are dispensable for tumor suppression. Mol Cell Biol (2006) 1.08
Mdm2 mutant defective in binding p300 promotes ubiquitination but not degradation of p53: evidence for the role of p300 in integrating ubiquitination and proteolysis. J Biol Chem (2001) 1.03
Topors, a p53 and topoisomerase I binding protein, interacts with the adeno-associated virus (AAV-2) Rep78/68 proteins and enhances AAV-2 gene expression. J Gen Virol (2002) 0.94
Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J (2006) 0.89
Autophagy promotes tumor cell survival and restricts necrosis, inflammation, and tumorigenesis. Cancer Cell (2006) 11.79
Role of autophagy in cancer. Nat Rev Cancer (2007) 10.88
Autophagy suppresses tumorigenesis through elimination of p62. Cell (2009) 9.95
Autophagy and metabolism. Science (2010) 8.10
Activated Ras requires autophagy to maintain oxidative metabolism and tumorigenesis. Genes Dev (2011) 7.43
Autophagy suppresses tumor progression by limiting chromosomal instability. Genes Dev (2007) 7.41
Autophagy mitigates metabolic stress and genome damage in mammary tumorigenesis. Genes Dev (2007) 6.35
Principles and current strategies for targeting autophagy for cancer treatment. Clin Cancer Res (2011) 5.40
DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev (2003) 3.67
Role of autophagy in cancer: management of metabolic stress. Autophagy (2007) 3.40
Ammonia derived from glutaminolysis is a diffusible regulator of autophagy. Sci Signal (2010) 3.38
Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell (2005) 3.19
Bax and Bak independently promote cytochrome C release from mitochondria. J Biol Chem (2002) 3.18
A noncanonical mechanism of Nrf2 activation by autophagy deficiency: direct interaction between Keap1 and p62. Mol Cell Biol (2010) 2.93
Autophagy suppresses progression of K-ras-induced lung tumors to oncocytomas and maintains lipid homeostasis. Genes Dev (2013) 2.90
Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev (2004) 2.69
BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell (2002) 2.64
Metabolic catastrophe as a means to cancer cell death. J Cell Sci (2007) 2.58
Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes Dev (2002) 2.29
The role for autophagy in cancer. J Clin Invest (2015) 2.11
Autophagy in tumorigenesis and energy metabolism: friend by day, foe by night. Curr Opin Genet Dev (2011) 2.09
Autophagy sustains mitochondrial glutamine metabolism and growth of BrafV600E-driven lung tumors. Cancer Discov (2013) 2.08
Autophagy-mediated tumor promotion. Cell (2013) 2.08
ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J (2007) 1.90
Association of Bax and Bak homo-oligomers in mitochondria. Bax requirement for Bak reorganization and cytochrome c release. J Biol Chem (2002) 1.82
Human IRGM regulates autophagy and cell-autonomous immunity functions through mitochondria. Nat Cell Biol (2010) 1.76
A mouse model system to genetically dissect the molecular mechanisms regulating tumorigenesis. Clin Cancer Res (2006) 1.74
Tumor suppression by autophagy through the management of metabolic stress. Autophagy (2008) 1.71
Glutamine-driven oxidative phosphorylation is a major ATP source in transformed mammalian cells in both normoxia and hypoxia. Mol Syst Biol (2013) 1.56
BH3-only proteins in control: specificity regulates MCL-1 and BAK-mediated apoptosis. Genes Dev (2005) 1.55
NBK/BIK antagonizes MCL-1 and BCL-XL and activates BAK-mediated apoptosis in response to protein synthesis inhibition. Genes Dev (2007) 1.53
Exploiting different ways to die. Genes Dev (2004) 1.51
Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene (2005) 1.51
Immortalized mouse epithelial cell models to study the role of apoptosis in cancer. Methods Enzymol (2008) 1.47
Therapeutic starvation and autophagy in prostate cancer: a new paradigm for targeting metabolism in cancer therapy. Prostate (2008) 1.45
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
Role of autophagy in cancer prevention. Cancer Prev Res (Phila) (2011) 1.43
Role of autophagy in breast cancer. Autophagy (2007) 1.39
Autophagy suppresses RIP kinase-dependent necrosis enabling survival to mTOR inhibition. PLoS One (2012) 1.37
ASAP, a novel protein complex involved in RNA processing and apoptosis. Mol Cell Biol (2003) 1.34
Why sick cells produce tumors: the protective role of autophagy. Autophagy (2007) 1.34
Autophagy opposes p53-mediated tumor barrier to facilitate tumorigenesis in a model of PALB2-associated hereditary breast cancer. Cancer Discov (2013) 1.32
Role of the polarity determinant crumbs in suppressing mammalian epithelial tumor progression. Cancer Res (2008) 1.30
Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem (2009) 1.30
Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation. J Biol Chem (2006) 1.30
Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol (2002) 1.24
Autophagic cell death unraveled: Pharmacological inhibition of apoptosis and autophagy enables necrosis. Autophagy (2008) 1.14
Mutational landscape of the essential autophagy gene BECN1 in human cancers. Mol Cancer Res (2014) 1.13
Liquid chromatography-high resolution mass spectrometry analysis of fatty acid metabolism. Anal Chem (2011) 1.13
Production of membrane proteins for NMR studies using the condensed single protein (cSPP) production system. J Struct Funct Genomics (2009) 1.12
Immunohistochemical detection of cytoplasmic LC3 puncta in human cancer specimens. Autophagy (2012) 1.12
Assessing metabolic stress and autophagy status in epithelial tumors. Methods Enzymol (2009) 1.11
Arsenic inhibits autophagic flux, activating the Nrf2-Keap1 pathway in a p62-dependent manner. Mol Cell Biol (2013) 1.10
Effect of dual inhibition of apoptosis and autophagy in prostate cancer. Prostate (2012) 1.07
A mouse mammary epithelial cell model to identify molecular mechanisms regulating breast cancer progression. Methods Enzymol (2008) 1.05
Measurement of subcellular texture by optical Gabor-like filtering with a digital micromirror device. Opt Lett (2008) 1.04
Induction of apoptosis by diterpenes from the soft coral Xenia elongata. J Nat Prod (2007) 1.03
Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res (2009) 1.01
E1A sensitizes cells to tumor necrosis factor alpha by downregulating c-FLIP S. J Virol (2003) 1.01
Akt-dependent expression of NAIP-1 protects neurons against amyloid-{beta} toxicity. J Biol Chem (2005) 0.98
Autophagy regulates keratin 8 homeostasis in mammary epithelial cells and in breast tumors. Mol Cancer Res (2010) 0.96
Regulation of the mitochondrial checkpoint in p53-mediated apoptosis confers resistance to cell death. Oncogene (2002) 0.92
Therapeutic targeting of death pathways in cancer: mechanisms for activating cell death in cancer cells. Adv Exp Med Biol (2008) 0.91
A novel proteomic coculture model of prostate cancer cell growth. Proteomics (2004) 0.89
Defective ubiquitin-mediated degradation of antiapoptotic Bfl-1 predisposes to lymphoma. Blood (2010) 0.89
Epothilone induced cytotoxicity is dependent on p53 status in prostate cells. Prostate (2004) 0.89
A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res (2005) 0.88
Grm5 expression is not required for the oncogenic role of Grm1 in melanocytes. Neuropharmacology (2005) 0.87
Essential roles of BCCIP in mouse embryonic development and structural stability of chromosomes. PLoS Genet (2011) 0.86
Autophagy for the avoidance of degenerative, inflammatory, infectious, and neoplastic disease. Curr Opin Cell Biol (2010) 0.86
The continuing saga of p53--more sleepless nights ahead. Mol Cell (2005) 0.84
Ammonificins A and B, hydroxyethylamine chroman derivatives from a cultured marine hydrothermal vent bacterium, Thermovibrio ammonificans. J Nat Prod (2009) 0.84
Cancer: Mutant p53 and chromatin regulation. Nature (2015) 0.83
A randomized phase II trial of mitoxantrone, estramustine and vinorelbine or bcl-2 modulation with 13-cis retinoic acid, interferon and paclitaxel in patients with metastatic castrate-resistant prostate cancer: ECOG 3899. J Transl Med (2010) 0.82
Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach. Mol Cancer Ther (2011) 0.80
Apoptosis-inducing galactolipids from a cultured marine diatom, Phaeodactylum tricornutum. J Nat Prod (2008) 0.79
Augmentation of apoptosis by the combination of bleomycin with trifluoperazine in the presence of mutant p53. J Exp Ther Oncol (2002) 0.79
FLIPping the balance between apoptosis and proliferation in thyroid cancer. Clin Cancer Res (2006) 0.77
Targeting mutant p53 through the mevalonate pathway. Nat Cell Biol (2016) 0.76
Ammonificins C and D, hydroxyethylamine chromene derivatives from a cultured marine hydrothermal vent bacterium, Thermovibrio ammonificans. Mar Drugs (2012) 0.76
Q&A: Eileen White on understanding autophagy. Cancer Discov (2012) 0.76
Bathymodiolamides A and B, ceramide derivatives from a deep-sea hydrothermal vent invertebrate mussel, Bathymodiolus thermophilus. J Nat Prod (2011) 0.75
Correction: Elevated p62/SQSTM1 determines the fate of autophagy-deficient neural stem cells by increasing superoxide. J Cell Biol (2016) 0.75
Tumor suppression by autophagy through the management of metabolic stress. Autophagy (2008) 0.75
60 Second With Eileen White. Nurs Times (2016) 0.75
p53: master of life, death, and the epigenome. Genes Dev (2017) 0.75